CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure

Representatives of CytomX Therapeutics, Inc. are hosting an investor conference call to present the information in the presentation slides, attached hereto as Exhibit 99.1, to the investor community during the European Society for Medical Oncology (“ESMO”) 2018 Congress on October 22, 2018. A copy of the presentation slides, including a slide setting forth certain cautionary language intended to qualify the forward-looking statements included in the presentation, is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Security Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.Financial Information and Exhibits

(d) Exhibits

CytomX Therapeutics, Inc. Exhibit
EX-99.1 2 ctmx-ex991_97.htm EX-99.1 ctmx-ex991_97.pptx.htm PROCLAIM CX-072 ESMO 2018 Clinical Presentations October 22,…
To view the full exhibit click here

About CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX)

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program.